AlloNK Shows CAR T-Comparable Efficacy in Autoimmune Diseases, Set for EULAR Late-Breaking Presentation
ARTV has more than doubled off its 52-week low of $1.47 on elevated volume (2.3× avg).
Summary
Artiva Biotherapeutics announced multiple upcoming data presentations for its lead program, AlloNK (AB-101), at the EULAR 2026 Congress. The most impactful is a late-breaking oral presentation highlighting clinical efficacy comparable to autologous CAR T-cell therapy in rheumatologic diseases. This news provides crucial, more specific validation of the positive initial clinical data for AlloNK in autoimmune diseases that the company reported on May 8th. That earlier announcement was immediately followed by a $300 million public offering and a significant $100 million investment from RA Capital. Achieving efficacy comparable to autologous CAR T-cell therapy with an allogeneic, off-the-shelf product like AlloNK represents a major clinical and commercial breakthrough, suggesting a potentially highly effective, yet more accessible and safer, treatment option. This strong data significantly de-risks the program and enhances its market potential, justifying the recent capital raise and investor confidence. Investors will closely watch the full data presentation at EULAR from June 3-6 and the company's webcast on June 8th for further details and confirmation of these promising results.
At the time of this announcement, ARTV was trading at $8.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $211.3M. The 52-week trading range was $1.47 to $14.53. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.